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In our study, which included few patients with multiple myeloma, HCV infection was not found in any patients. The lower prevalence Leukemia of HCV infection in B cell neoplasms other than B-cell lymphoma has been recently confirmed by Zuckerman et al. 2 In conclusion, our findings show a modest increase of prevalence of HCV infection among patients with B cell lymphoproliferative disorders in a very homogeneous population of southern Italy. These data question the role of HCV in the pathogenesis of this neoplasm. Thus, the clonal B cell expansion in patients with chronic HCV infection may be only one of many factors necessary for the full expression of malignant conditions. Moreover, the role of HCV infection perhaps depends on the variability of its pathogenicity according to the viral load and genotype. Other factors including genetic, immunologic, or environmental aspects that can vary widely across geographic regions, are probably involved in the pathogenesis of these disorders. sary for constant replacement of senescent mature cells or to respond to a stress, like hemorrhage or infection. This implies precise regulation of the balance between cell growth, survival and differentiation, regulated mainly by soluble or membrane-bound cytokines.
Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis
1 Immature hematopoietic cells are fragile and strictly cytokine-dependent. Macrophage colony-stimulating factor (M-CSF) has been proved to be able to rescue normal hematopoietic progenitors and some myeloid leukemia blasts from death. 2 Recent evidence has indicated that proteins of the inhibitor of apoptosis (IAP) family, whose expression might be under the regulation of NF-B, can block apoptotic events by directly binding and inhibiting selected caspases. A potent mam-
Figure 1
Effects of M-CSF on the expression of apoptosis-related proteins in myeloid leukemia cells. (a) Representative pictures from P1 to 5; (b) representative pictures from P6 to 8; (c) representative pictures from P9 to 12. After protein determination, total cell lysates (5 × 10 5 ) were boiled in 2 × reducing SDS loading buffer of equal volume for 10 min. The samples were subjected to one-dimensional SDS-PAGE. After eletrophoresis, proteins were transferred to a 0.45 m pore-size nitrocellulose membrane at 40 V for 2 h. Non-specific binding sites on the nitrocellulose membrane were blocked by incubation in blocking buffer (5% (w/v) non-fat dried milk) for 1 h at 37°C. The blots were washed once with Tris-buffered saline (10 mM Tris/HCl (pH7.5)/150 mM NaCl) and incubated with the primary antibody for 1 h at 37°C or overnight at 4°C. After the removal of excess primary antibody with three washes, the blots were incubated with a secondary antibody (goat anti-mouse or goat anti-rabbit antibodies conjugated with horseradish peroxidase). The membrane was developed with enhanced chemiluminescence reagent and exposed to Hyperfilm-ECL (Amersham Life Science, USA) for detection. Densitometry readings of the blots are expressed in 'Ratio to Actin (%)' below the pictures. Anti-(human XIAP) antibody was a product of Medical and Biological Laboratories (Naka-ku, Nagoya, Japan). Anti-Bcl-2, anti-caspase-3 and anti-Bax antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Figure 2
Suppression of XIAP (a) and induction of apoptosis (b) in day 10 M-respond cells by CAPE: representative pictures from P9 to 12. CAPE was obtained from Alexis Biochemicals (San Diego, CA, USA). After the removal of exogenous M-CSF, day 10 M-respond cells were cultured in the presence of CAPE (25 g/ml) or equal volume of DMSO for various periods as indicated. At the end of the incubation period, cell viability was determined by propidium iodide staining. Cell lysates from CAPE-treated or DMSO-treated samples were further subjected to immunoblot analysis with anti-XIAP antibody and anti-caspase-3 antibody. For apoptosis assay, leukemia cells were harvested, washed and resuspended to a final density of 10 6 /ml in ice-cold 70% ethanol for a minimum of 18 h. After washing with PBS, the pellet was stained with propidium iodide (PI; Sigma) at a concentration of 50 g/ml in PBS containing 0.002% Triton-X 100 and 100 U/ml RNase A (Sigma, St Louis, MO, USA) and incubated at room temperature in the dark for 30 min. Then, the cells were analyzed in a fluorescence-activated cell sorter (Becton Dickinson FACS, USA). malian IAP is X-linked IAP (XIAP), for which the mechanism of action involves the direct binding and inhibition of caspase-3 and caspase-7, two key effector proteases of apoptosis. 3, 4 What role XIAP plays in M-CSF-mediated anti-apoptosis mechanism is of interest. Previous studies suggest that XIAP is one of the anti-apoptotic regulators that confer resistance on mature macrophage induced by M-CSF in primary cultures of murine bone marrow cells. 5 In this work, we try to investigate whether XIAP plays the same role in M-CSF-mediated survival of myeloid leukemia blasts.
First, we examined the effects of M-CSF on the survival and proliferation of myeloid leukemia cells. The stimulative effects of optimal concentrations of M-CSF on the survival and proliferation of myeloid leukemia cells (n = 12 cases) in vitro were assessed (MTT incorporation) in comparison with the cultures without exogenous stimulus. M-CSF promoted cell survival and proliferation in four of 12 cases (MTT ratio Ͼ2.0). Some (three of 12 cases) of the leukemia cells that showed weak responsiveness to M-CSF (MTT ratio Ͻ2.0) remained alive in vitro, while others (five of 12 cases) underwent apoptosis in 7-10 days as determined by propidium iodide staining. These three groups of leukemia cells are called M-respond, M-alive and M-apoptosis, respectively, in the subsequent statement. M-CSF induced attachment and/or CD11b up-regulation in seven of 12 cases, ie M-respond and M-alive cells. After incubation with 100 ng/ml M-CSF for 10 days, more than 90% of the adherent cells exhibited morphological characteristics of macrophage (Table 1 and data not shown).
To gain insight into the mechanisms of distinct anti-apoptosis ability, we studied the expression of a number of apoptosis-related proteins (XIAP, caspase-3, Bcl-2 and Bax) in M-CSF-induced myeloid leukemia cells. Untreated leukemia cells displayed significant levels of these apoptosis-related gene products. In M-apoptosis cells, in vitro culture resulted in a significant degradation of XIAP and Bcl-2. Consistent with this, the level of pro-caspase-3 was decreased. However, there was no significant change in the level of Bax (Figure 1a) . In Malive cells, incubation with 100 ng/ml M-CSF had little effect on the levels of these apoptosis-related proteins (Figure 1b) . In M-respond cells, M-CSF significantly up-regulated the levels of XIAP and Bcl-2 but had little effect on the level of caspase-3. The level of Bax increased modestly during the process (Figure 1c) .
The preceding experiment suggests that up-regulation of XIAP and Bcl-2 is associated with the growth-promoting effects of M-CSF in myeloid leukemia cells. Consistent with these data, Lin et al 5 reported that resistance of M-CSF-induced bone marrow-derived macrophages to apoptosis is associated with an increase in the level of XIAP, and treatment of mature macrophages with XIAP anti-sense oligonucleotides or NF-B inhibitor significantly abolished their resistance to apoptosis. To investigate whether the up-regulation of XIAP contributes to the survival of M-respond cells, we used caffeic acid phenylethyl ester (CAPE), a specific inhibitor of NF-B, 5 to block the /ml) were then cultured in RPMI-1640 containing 15% (v/v) FBS (fetal bovine serum, HyClone Laboratory, USA). b The leukemia cells were seeded into 96-well plates, with a density of 1 × 10 5 cells per well. The cells were cultured for 10 days with or without 100 ng/ml M-CSF (Cetus Corporation, Emeryville, CA, USA), then 10 l MTT (Sigma, 5 mg/ml) was added to each well; 4 h later, an equal volume of 10% SDS-10 mM HCl was added to dissolve the blue crystals of formazan. Then the samples were measured at OD 570nm by an ELISA reader (Dynatech Laboratories, USA). All experiments were performed in triplicate, and data are expressed as means ± s.d. Data obtained from cultures with 100 ng/ml were set against those without M-CSF. M-CSF is believed to promote the survival and proliferation of leukemia cells if the ratio is above 2.0. expression of XIAP induced by M-CSF. As expected, treatment of day 10 M-respond cells with 25 g/ml CAPE, which was dissolved in dimethyl sulfoxide (DMSO), resulted in a marked decrease in the level of XIAP after the removal of M-CSF, while treatment with equal volume of DMSO had no significant effect on the level of XIAP. The decrease in XIAP induced by CAPE treatment was accompanied by cell death through an apoptotic mechanism (Figure 2) . Furthermore, significant XIAP down-regulation occurred as early as 8 h after CAPE treatment in M-CSF-induced bone marrow-derived macrophages, while obvious cell death appeared much later (samples from normal people, our unpublished data). Therefore, the decreased expression of XIAP did not seem to be a nonspecific consequence of the death process. Since XIAP is the most potent mammalian IAP and is significantly up-regulated in M-respond cells, the fact that CAPE induced XIAP down-regulation and apoptosis of M-respond cells suggests that XIAP might play a role in M-CSF-mediated survival of myeloid leukemia cells. However, as NF-B may regulate the expression of a large number of genes, including IAPs other than XIAP, 3 further demonstration is needed to prove that the decreased expression of XIAP resulted in the cell death induced by CAPE. Also, XIAP is probably not the only parameter that accounts for the ability of leukemia cells to survive in culture conditions; it may co-operate with other antiapoptotic proteins. Bcl-2 may be such a component since it was also up-regulated by M-CSF in M-respond cells. Beijing, PR China vated after exposure to DNA damaging agents. 1 A hallmark of many tumor cells is that the p53 gene is mutated and expressed at greatly elevated levels. We have been interested in determining the cause of lack of expression of the p53 gene in cell lines derived from myeloid leukemias. Although numerous tumor types express elevated levels of mutant p53, it has been demonstrated that some astrocytomas, 2 a high proportion of breast cancers 3 and many human myeloid leukemias do not express detectable levels of p53 mRNA. 4 The mechanism responsible for the silencing of p53 expression in myeloid tumors remains unknown. The loss of p53 gene expression in these cells is likely to be an important step in cancer progression and could result from cis-acting mutations within the regulatory regions of the gene or
Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene

